Turn Therapeutics raises $1.35M from existing backers
What's the deal? Turn Therapeutics (NASDAQ: TTRX) has raised $1.35 million in gross proceeds through a private placement of common stock, the pharmaceutical company announced on 14 August 2026. It sold 135,000 shares at $10.00 each to accredited investors.
Who's backing it? The buyers were existing series and seed investors — a sign of continued support from the company's established shareholder base. The placement was made under Section 4(a)(2) of the Securities Act and Regulation D.
What's the money for? The proceeds support Turn Therapeutics' operations and extend its financial runway. For an early-stage drug developer, the cash strengthens its position without a public offering.
The fine print: The company granted investors registration rights covering the shares, which paves the way for their eventual resale.
The signal: Small, insider-led private placements let listed early-stage biotechs raise capital quickly and quietly, tapping known backers rather than the open market. For Turn Therapeutics, the cash injection is modest but reflects existing investors' willingness to double down.
Read more: MiniChart
Image credit: U.S. Army Combat Capabilities Development Command
